Invest in Simplify Genomics

More than 20 years after the first human genome was sequenced, genomics is stalled in a data flood. Human genomes are sequenced quickly and inexpensively, yet clinicians are left reviewing the first page of a highly limited report, leaving powerful data buried and unusable.

Demand for whole genome sequencing is rising rapidly as sequencing costs decline. The challenge has shifted from a sequencing problem to a data problem as the industry struggles to make clinical sense of all the genomic information (6.4B pieces of data from one human genome!).

Currently, the interpretation of the data is done by bioinformaticians and genomic scientists making subjective decisions on a tiny subset of data, and this reliance on people to make decisions is driving costs back up.

As an industry, we are on the precipice of discovery that will enable the identification, creation, and commercialization of vastly improved patient treatments.

By tapping into the full power of the genome, clinicians can quickly assess genomic similarities between patients, providing the right treatment to the right patient and limiting side effects. We believe this will revolutionize healthcare!

We believe Simplify Genomics has created the next-generation platform to realize these discoveries and finally make use of the data flood. 

Solving the Data Problem with Smart Genome

Over the last 7 years, Simplify Genomics has built Smart Genome, an automated genome reporting platform designed for scale to empower genomics in healthcare. Simply put, it makes practical clinical use of deep genomic data, finally bringing healthcare into the future.

Since 2018, our platform has curated over 7,000 genes and millions of variants, producing over 10,000 clinically actionable whole genome reports. AI-driven and validated, our platform supports seamless content expansion, with nine versions released over seven years.

Smart Genome was developed by an expert team under Craig Venter – the first person to sequence the human genome – and leveraged decades of insight to create our platform.

Our Technology Stack

Simplify Genomics’ technology is a three-tiered suite to empower the future of genomics in healthcare.

1. Simplify Genome: Clinical whole genome reporting

CLIA-certified and CAP-accredited dry laboratory that delivers actionable insights from whole genome sequencing. Our content is AI-informed and explainable, ensuring scalable, fast, and reproducible clinical reporting.

2. Simplify Search: Fast, accurate, insightful genome exploration

An AI technology platform that quickly provides access to raw genetic data, clinical information, and the latest insights in genomics. Similar to Google, users can access information through a user-friendly interface that queries hundreds of millions of genomic variants at the speed of thought.

3. Simplify Data: Multi-source, rich data repository

An aggregation of public, proprietary, and clinical data that empowers discovery and research, serving as the foundation of the Genome and Search platforms.

For a more technical look at our Search platform, see the following video:

With our groundbreaking solutions, we can finally interpret genomic data quickly enough and at the scale needed for clinical actionability.

With the right data, we can match genetically similar patients to predictable outcomes, putting powerful science behind personalized healthcare. This technology moves us toward personalized medicine and can extend lifespans.

Furthermore, our platform uses AI to quickly generate deeper reports, eliminating the need for costly manual work while significantly reducing time and expenses.

Proven Company 

Simplify Genomics started in 2016 under our former parent company, Human Longevity. Founded in 2013 by Craig Venter, the person credited with sequencing the first human genome, Human Longevity focused on developing solutions around the whole genome, with over $400 million in investment into the parent company. 

In 2022, Simplify Genomics spun out of Human Longevity, leveraging years of expertise and $90 million of development to create our platform. Today, Human Longevity exclusively uses Simplify Genomics reports to guide clinical decisions for its Longevity Program. 

Simplify has accomplished the following: 

1. Built an automated AI system to produce clinical reports from raw genomic data seamlessly.
2. Created a market-leading comprehensive genomic screening report that covers multiple diseases.
3. Developed breakthrough search technology for instant analysis of genomic and clinical data.
4. Assembled a database with over 35k whole genomes and 400 million unique variants – expected to surpass 100,000 whole genomes and more than 1 billion distinct variants in the next six months!
5. Compiled a curated database of 1.6 million genetic variants, linking each to diseases and assessing their risk level.

We have demonstrated initial market acceptance and revenue generation, generating between $1.5M and $2M of revenue annually, primarily from Human Longevity.

(Forward-looking projections not guaranteed)

Market Demanding Change

As sequencing prices rapidly decline after years of stagnation, the healthcare industry is moving to whole genome sequencing as a backbone, creating optimal timing for Simplify.

Our initial target market is the large and growing concierge medicine and executive health market, which will use our reports as an addition to their current offerings. This market is eager for new content to differentiate itself and better treat its patients and our screening reports give them that edge. We are at the forefront of this transition.

We believe this target market will allow Simplify to achieve positive cash flow in under 12 months and then expand into additional markets. Please note that future projections aren't guaranteed.

Profitable Business Model

Simplify is a rare opportunity in the healthcare technology sector. Our profitability may be extremely close on the front end, and our valuation growth may be exponential on the back end. This is possible due to the $90M+ development funding prior to the spin-out and our team's deep experience.  

As Simplify’s solution is adopted, there are additional monetization streams, including significant recurring revenue opportunities through a subscription model. 

(Forward-looking projections not guaranteed)

Leading the Competition

Simplify Genomics is entering a market poised for disruption. Current products have limited clinical utility. Our Smart Genome platform paves the way for something entirely new by equipping clinicians to fully leverage raw genomic data, positioning us to be a leader in an industry primed for major change.

Our report is much broader, more clinically actionable, and lower in cost. Additionally, our search engine provides groundbreaking access to information that revolutionizes patient care by utilizing raw data beyond the clinical report at the speed of thought.

Future Opportunities

As a lean company, we are hyper-focused on the short-term plan and commercializing our market-leading report. That being said, our full platform suite has significant future upside opportunities that can dramatically increase the business's enterprise value.

Simplify can address multiple commercial avenues, such as an end-to-end reporting solution, large-scale Simplify Search adoption, and subscription models.

There is ample industry precedent for acquisition in the healthcare technology sector - a likely outcome for Simplify Genomics in the foreseeable future.

Precedent Acquisitions

• Pierian was acquired by Velsera
• Emedgene was acquired by Illumina
• Nof1 was acquired by Qiagen
• DeepLens was acquired by Paradigm
• Trapelo Health was acquired by NeoGenomics

Team of Industry Experts

Simplify’s team consists of industry veterans with experience building and selling a health tech platform. Previously, working together at Human Longevity under industry pioneer Craig Venter, they developed the platform that is now Smart Genome, giving them deep expertise in its code and architecture.

Our co-founder and CEO, Travis Lacey, has a background in business, including as an investment banker. Lacey built a successful oncology platform that sequenced high-quality data from tumor tissue and interpreted it into clinically relevant information for drug development. In 2020, it was acquired by NeoGenomics Laboratories, significantly exceeding investor expectations.

We have successfully leveraged the strength of our lean but passionate team to get Simplify to its current state.

The Use of Funds

Today, Simplify Genomics is raising $5 million to expand commercially and continue the product development of Smart Genome.

The investment thesis has been de-risked, given that Simplify has a clear market problem, a proven solution, a validated technology platform, CLIA certification and CAP accreditation, and initial market acceptance. In addition, we have $90M in prior development funding, and a clean cap table, making this opportunity a high-potential investment. 

As genomics takes center stage in clinical, biotech and pharma markets, Simplify Genomics is strategically positioned to lead the future of personalized medicine. Join us in transforming genomic data to dramatically improve patient outcomes at the speed of thought!